Physician profile
Beth Brunsman
NPI 1114256211
$7,317.22
in general payments reported to CMS, 2019-2025
25 companies · $1,295 in 2025
The $1,295 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,460 · 2022: $1,487 · 2023: $1,495 · 2024: $1,581 · 2025: $1,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,370.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,092.14 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,457.62 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $845.77 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $608.43 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $547.50 | 2021-2025 | |
| Pfizer INC. | $333.24 | 2021-2025 | |
| Abbott Laboratories | $276.89 | 2022-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $219.06 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $172.26 | 2022 | |
| Bausch Health US, LLC | $125.39 | 2021-2023 | Aplenzin, Wellbutrin |
| Takeda Pharmaceuticals U.S.A., INC. | $119.93 | 2021-2022 | |
| Exact Sciences Corporation | $107.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $51.22 | 2024-2025 | Otezla, Repatha, Otezla |
| Biohaven Pharmaceuticals, INC. | $50.78 | 2021 | |
| Amarin Pharma, INC. | $48.71 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $41.28 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.60 | 2023 | Xifaxan |
| Medtronic, INC. | $34.57 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.67 | 2021 | |
| Sanofi-Aventis U.S. LLC | $23.56 | 2025 | |
| Horizon Therapeutics Plc | $21.45 | 2021 | |
| Vivus LLC | $20.56 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.79 | 2024 | Quviviq |
| Merck Sharp & Dohme LLC | $17.08 | 2022 | |
| Eisai INC. | $15.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Brunsman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.